Efficacy and Safety Study of HS-10542 for IgA Nephropathy

NCT07474636 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

IgAN
Immunoglobulin A Nephropathy (IgAN)
Glomerular Disease

Interventions

DRUG: HS-10542 High Dose
DRUG: HS-10542 Low Dose
DRUG: Placebo

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.